|
Synonyms: FE 999301 | FE-301 | FE-999301 | TJ301
Compound class:
Peptide or derivative
Comment: Olamkicept is a recombinant protein that fuses the extracellular domain of the signal transducing subunit of the IL-6 receptor, IL-6Rβ (glycoprotein 130, gp130), to a human IgG Fc fragment [3]. The full construct is a dimer of covalently linked identical peptide chains. Mechanistically olamkicept acts as an inhibitor of the IL-6 signalling pathway. Olamkicept inhibits trans signalling by the soluble IL-6 receptor (sIL-6R) [1], a mechanism that is involved in human inflammatory and autoimmune diseases [2]. It is hypothesised to be clinically effective in reducing disease signs and symptoms whilst not being detrimental to the role of IL-6 in the acute immune response to infection.
|
| No information available. |
Summary of Clinical Use  |
| A Phase 2 clinical trial evaluating olamkicept (using research code TJ301) in patients with active ulcerative colitis is registered with ClinicalTrials.gov and is currently in the recruiting stage (as of April 2019- see NCT03235752). |
| Mechanism Of Action and Pharmacodynamic Effects |
| IL-6 is a key cytokine in the pathogenesis of autoimmune diseases such as inflammatory bowel disease and rheumatoid arthritis. Olamkicept is a selective inhibitor of this proinflammatory pathway. It is reported that in intestinal inflammation driven by IL-6, neutralising sIL-6R trans signalling releases intestinal T cells from IL-6-sIL-6R-induced resistance to apoptosis, thereby reducing the number of activated T cells and reducing the overall level of inflammation [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03235752 | Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis | Phase 2 Interventional | I-Mab Biopharma HongKong Limited | ||
